transgender status was not a predictor of prostate cancer-related death. These findings highlight the importance of racial diversity in genomic profiling and clinical trials. Men aged 60-69 years had a decreased risk of death with the addition of androgen deprivation therapy. The adoption of polyethylene glycol hydrogel spacer use in prostate cancer care has been slower in Black patients. Guideline-concordant androgen deprivation therapy is associated with a survival benefit in high-risk prostate cancer. Patients who underwent radical prostatectomy also had a higher likelihood of decision regret. Both Fluciclovine and PSMA PET/CT guided radiation therapy would significantly change pre-PET radiation therapy volumes. P-CARE integrates genetics, family history, and ancestry to offer a more objective risk assessment. After 10 years, 3.3% of patients who were recurrence-free developed distant metastasis. High-risk genomic classifiers were associated with a 10-fold higher risk of prostate cancer. The use of gender-affirming hormone therapy was associated with lower PSA levels compared with cisgender men. MRI guidance helps to reduce the amount of healthy tissue targeted during radiation therapy for prostate cancer. Advanced radiotherapy using fewer, stronger doses delivered similar quality-of-life outcomes and side effects. The results revealed that Black men had greater microvascular dysfunction compared with White males. prostate cancer cases is expected globally, with numbers doubling to 2.9 million and deaths increasing by 85% Black men are more likely to be diagnosed with and die from prostate cancer. "Prostate cancer cells (are) producing more cholesterol, which they divert to generate their own androgen." Black participants were significantly less likely to use NHT compared to other racial and ethnic groups. Researchers found that men from indigenous men were more likely to have higher PSA compared to non-Indigenous men. Asian PCa patients had longer median overall survival than White patients.